The Sjögren’s Foundation is proud to partner with the Foundation for the National Institutes of Health (FNIH) on a new three-year study focused on identifying biomarkers for Sjögren’s disease called The Molecular Characterization and Diagnostic Biomarkers of Sjögren’s Disease. This project is a three-year study that will bring together leading researchers from the National Institute of Dental and Craniofacial Research, academic centers, and industry partners. The goal is to identify new biomarkers that can lead to faster and more accurate diagnosis and help researchers design more effective clinical trials.
Through the discovery of novel, noninvasive biomarkers, investigators aim to:
- Enable earlier and more accurate diagnosis.
- Define disease subtypes based on molecular data.
- Improve patient selection for clinical trials and treatments.
- Identify potential new causes and drug targets.
Read more about the biomarkers project on FNIH.org
This initiative builds on the momentum of the AMP® AIM project, where the Foundation also serves on the steering committee to ensure the patient voice guides research. AMP® AIM is a large public–private partnership generating shared datasets to uncover the root causes of autoimmune diseases and ensure Sjögren’s is prioritized.
The Sjögren’s Foundation is on the steering committees of both the AMP® AIM and the biomarkers projects.
Too many of us go undiagnosed or misdiagnosed for far too long, and even after diagnosis, we face a lack of effective treatments,” says Janet Church, President & CEO of the Sjögren’s Foundation. “This project offers real hope—not just for better understanding of the disease, but for a future where patients are seen, heard and helped with the right care at the right time.
The Sjögren’s Foundation is proud to partner with the Foundation for the National Institutes of Health (FNIH) on a new three-year study focused on identifying biomarkers for Sjögren’s disease called The Molecular Characterization and Diagnostic Biomarkers of Sjögren’s Disease. This project is a three-year study that will bring together leading researchers from the National Institute of Dental and Craniofacial Research, academic centers, and industry partners. The goal is to identify new biomarkers that can lead to faster and more accurate diagnosis and help researchers design more effective clinical trials.
Through the discovery of novel, noninvasive biomarkers, investigators aim to:
Read more about the biomarkers project on FNIH.org
This initiative builds on the momentum of the AMP® AIM project, where the Foundation also serves on the steering committee to ensure the patient voice guides research. AMP® AIM is a large public–private partnership generating shared datasets to uncover the root causes of autoimmune diseases and ensure Sjögren’s is prioritized.
The Sjögren’s Foundation is on the steering committees of both the AMP® AIM and the biomarkers projects.